Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer

NCT07008833 | Not Yet Recruiting DMC

• 2 other identifiers: 002/202401245.011245/2023-57
• Study Type: interventional
• Target: 336
• Locations: 1 country
• Sites: 1

Brief Summary

Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with muscle-invasive bladder cancer. The primary outcome is the evaluation of the non-inferiority of metastasis-free survival between the two treatments. The study population includes individuals of both sexes, aged 18 years and older, diagnosed with pure or predominant urothelial carcinoma. Participants will be randomized in a 1:1 ratio, with Arm 1 receiving maximal TURBT followed by neoadjuvant chemotherapy and radiotherapy, and Arm 2 receiving TURBT followed by neoadjuvant chemotherapy with cisplatin, followed by radical cystectomy and bilateral pelvic lymphadenectomy.

Conditions

Muscle Invasive Bladder Cancer

Keywords

Bladder cancer; Radiochemotherapy; Radical cystectomy

Outcome Measures

Primary Outcomes (1)

• Metastasis-free survival

  The primary outcome is the assessment of the non-inferiority of metastasis-free survival between radiochemotherapy and radical cystectomy.

  The time from the start of treatment until detection of 230 metastases in other organs or tissues outside the bladder (including pelvic lymph nodes).or until death from any cause of the patient, estimated to be up to 8 years

Secondary Outcomes (5)

• Overall survival

  The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

• Muscle-invasive bladder cancer-free survival

  The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

• Incidence of tumors in the upper tract (in both arms)

  The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

• Adverse Events assessment

  The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

• Quality of Life assessment

  The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

Study Arms (2)

Arm 1

OTHER

Maximum TURBT + neoadjuvant chemotherapy with cisplatin + radiotherapy

Procedure: Radiochemotherapy

Arm 2

OTHER

TURBT + neoadjuvant chemotherapy with cisplatin + radical cystectomy, bilateral pelvic lymphadenectomy + reconstruction

Procedure: Radical cystectomy

Interventions

Radiochemotherapy PROCEDURE

Maximum TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m². After 2-6 weeks of neoadjuvant chemotherapy, patients will receive radiotherapy for 4 weeks, with concomitant cisplatin at a dose of 40 mg/m² weekly.

Arm 1

Radical cystectomy PROCEDURE

TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m², followed by radical cystectomy, bilateral pelvic lymphadenectomy, and reconstruction with either a Bricker procedure or a neobladder.

Arm 2

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients ≥ 18 years of age.
• Pure or predominant urothelial carcinoma (including other histologic subtypes, with the exception of small cell carcinoma, as a minority component).
• Performance status of 0 to 1, according to the Eastern Cooperative Oncology Group (ECOG) criteria.
• Life expectancy of ≥ 3 months.
• Histologically confirmed T2, T3, or T4a stage bladder cancer (pure or predominant urothelial carcinoma) cN0 or cN1 or cN2 (if lymph nodes within the surgical and radiation fields and size ≤ 2 cm).
• Patients who are candidates for neoadjuvant cisplatin and have undergone TURBT (preferably maximal) prior to treatment.
• Adequate bladder function (defined as the ability to store and void urine effectively, without symptoms of dysfunction or incontinence).
• Neutrophil count ≥ 1500/mm³.
• Platelet count ≥ 100,000/mm³.
• Hemoglobin count \> 10 g/dL.
• Glomerular filtration rate greater than 40 mL/min.
• Serum bilirubin \< 1.5 times the upper limit of the normal reference range and SGOT and SGPT \< 1.5 times the upper limit of the normal reference range.
• Absence of comorbidities that contraindicate treatment.
• Capable of giving signed and dated informed consent prior to any mandatory study-specific procedures, sampling, and analyses, which includes compliance with the requirements and restrictions listed in the informed consent form and study protocol.
• Provide informed consent for genetic research prior to sample collection.

You may not qualify if:

• Presence of multiple primary tumors or multiple foci of carcinoma in situ (CIS) (including in the upper tract) that are not candidates for bladder preservation with radiochemotherapy (definition at the discretion of the investigator).
• Age \> 80 years.
• Pure adenocarcinoma or pure squamous carcinoma or pure small cell or large cell neuroendocrine carcinoma, micropapillary, sarcomatoid or nested.
• Metastatic or unresectable disease.
• Sensory neuropathy Grade ≥ 2.
• Hearing impairment Grade ≥ 2.
• Having a known additional malignancy that has progressed or required active treatment in the last 5 years, except superficial bladder cancer and/or carcinoma in situ, basal cell carcinoma of the skin or carcinoma in situ of the cervix.
• Clinically significant cardiovascular disease - functional class III-IV according to the New York Heart Association (NYHA) Classification of heart failure.
• Patients considered to be at high medical risk due to severe and uncontrolled disease, active or non-malignant systemic disease, and severe or potentially severe infection that may affect response to treatment or increase the risk of adverse events.
• Immunocompromised patients.
• Inflammatory bowel disease.
• Patients with known active hepatitis (i.e., hepatitis B or C).
• Patients receiving any prior systemic chemotherapy in the last 5 years for other tumors and at any time for muscle-invasive bladder cancer.
• Patients who have received prior systemic immunotherapy at any time, either in the setting of non-muscle-invasive bladder cancer or in treatment for other types of cancer.
• Prior pelvic radiotherapy.

Sponsors & Collaborators

• Brazilian Clinical Research Institute: lead
• Ministry of Science and Technology, Brazil: collaborator

Study Sites (1)

Brazilian Clinical Research Institute

São Paulo, São Paulo, 01404100, Brazil

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Interventions

Chemoradiotherapy; Cystectomy

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Combined Modality Therapy; Therapeutics; Drug Therapy; Radiotherapy; Urologic Surgical Procedures; Urogenital Surgical Procedures; Surgical Procedures, Operative

Central Study Contacts

Fernando C Maluf, MD

CONTACT

55 11 59047339; maluffc@uol.com.br

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Clinical outcomes will be independently ascertained by a Clinical Events Committee, whose members will not be aware of the study arm.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 20, 2025
• First Posted: June 6, 2025
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): December 1, 2031
• Study Completion (Estimated): February 1, 2032
• Last Updated: February 12, 2026

Record last verified: 2026-02

Locations

BR (1)